TNF and myocarditis: Since the New England Journal of Medicine first published the use of infliximab for fulminant myocarditis after immune checkpoint blockade in 2016, results from 18 patients using TNF-α antibodies for ICI-induced myocarditis have been reported (Tables 1 and 2) (71, 77–86).